Background. Cytomegalovirus (CMV) remains an important pathogen in transplant patients, and valacyclovir (VACV) prophylaxis 8 g/day has been used in high-risk CMV-seromismatched [D+/R−] renal transplant patients to decrease CMV disease. Neurotoxic adverse effects have limited its use, and the aim of the present study was to retrospectively evaluate low-dose VACV prophylaxis, 3 g/day for 90 days after transplantation, in 102 D+/R− renal transplant patients. Methods. We compared patient and graft survival rates up to 5 years after transplantation with the data from the Collaborative Transplant Study Group (CTS) database. The incidence of CMV disease, rejection and neurotoxic adverse effects was analyzed up to 1 year after transplantation. Results. The patient and graft survival rates up to 5 years were comparable with those derived from the CTS. CMV disease was diagnosed in 25% of the patients and 2% developed tissue-invasive CMV disease. The rejection frequency was 22% and neurotoxic adverse effects were seen in 2% of the patients. Conclusions. Low-dose VACV prophylaxis (3 g/day) for 90 days post-transplantation results in high patient and graft survival rates and reduces the incidence of CMV disease. Neurotoxic adverse effects are minimal. We believe that low-dose VACV prophylaxis should be considered to form one of the arms in future prospective comparison studies for the prevention of CMV disease in the high-risk D+/R− population of renal transplant patients.
A B S T R AC T
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I N T RO D U C T I O N
Renal transplantation has become a successful treatment for end-stage renal disease, with 1-year patient and graft survival of almost 100% in living donor transplants, and ∼95 and 90%, respectively, in deceased donor transplants [1, 2] . However, cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality. The risk of CMV infection after renal transplantation varies between 36 and 100% [3] . CMV infection can cause symptoms from mild febrile illness to lethal disseminated disease, but can also affect rejection frequency and graft survival [4] [5] [6] [7] . It is therefore important to reduce the incidence of CMV infection and disease with prophylactic or pre-emptive strategies. The CMV serostatus of both recipient (R) and donor (D) has a major impact on the risk of developing CMV disease. The risk ranges from 5-10% in D−/R− [8] to 15-25% in D+/R+ and D−/R+, and >50% in the high-risk D+/R− population [9] . Initially, acyclovir (ACV) and ganciclovir (GCV) were used for prophylaxis [10, 11] . During the last 10-15 years, oral GCV [12] , valacyclovir (VACV) [13] and valganciclovir (VGCV) [14] have demonstrated superior results in reducing the incidence of CMV disease when compared with placebo or historical controls. There are few comparative studies, however, that have demonstrated a significant difference between the various prophylactic drugs. Factors such as cost, dosing intervals, the risk for emergence of resistance and the severity of adverse effects must therefore be taken into consideration when a prophylactic strategy is being designed. Nephrotoxic adverse effects are seen with both VACV and GCV/VGCV, but there are also haematological adverse effects with GCV and VGCV, whereas VACV prophylaxis with 8 g/day has been shown to produce major neurotoxic adverse effects such as hallucinations and confusion [13, 15, 16] . These neurotoxic adverse effects are dependent on dose and renal function [17] and could possibly be avoided with a low-dose VACV prophylaxis protocol, such as 3 g/day. Low-dose VACV has been used in three studies: two retrospective studies [18, 19] and one prospective study [20] . The results were promising regarding CMV disease and rejection, with no evidence of major neurotoxic adverse effects; however, the number of patients involved in these studies was small. In the present study, we have retrospectively studied all CMV-mismatched renal transplant patients at Uppsala University Hospital over a 10-year period. Low-dose VACV (3 g/day) prophylaxis was used in D+/R patients for 90 days after transplantation. Graft and patient survival was analyzed up to 5 years after transplantation and compared with data from the Collaborative Transplant Study Group (CTS). The incidence of CMV disease, biopsy-proven acute graft rejection (BPAR) and major neurotoxic adverse effects were analyzed up to 1 year after transplantation.
S U B J E C T S A N D M E T H O D S

Patients
All consecutive CMV-seronegative renal transplant recipients who received a renal transplant from a seropositive donor (D+/R−) between September 1998 and June 2007 at Uppsala University Hospital, Sweden, were studied, Institutional Review Board (IRB) approval number 2008/242. VACV prophylaxis was used for 90 days after transplantation, and the follow-up period was at least 1 year after transplantation. Patients receiving a combined kidney-pancreas transplantation and those included in an ABO bloodgroup incompatibility study were excluded. All medical charts were examined with regard to CMV infection, CMV disease, CMV treatment, graft rejection and neurotoxic adverse effects up to 1 year after transplantation. Graft and patient survival, demographics and other baseline characteristics of the included patients were compared with the corresponding data from the CTS cohort of D+/R− patients receiving a renal transplant during the same period, September 1998-June 2007 (Table 1) .
Immunosuppressive treatment
Several different standard immunosuppressive protocols were used during the study period; most commonly induction therapy (65%), consisting of a monoclonal IL-2 receptor blocker (basiliximab or daclizumab), either followed by cyclosporin (41%) or tacrolimus (24%). Cyclosporin (22%) or tacrolimus (13%) without induction was also used, and all patients received prednisolone in tapering doses.
Graft rejection
Graft rejection had to be biopsy confirmed (BPAR) and was classified according to the Banff criteria. Rejection was treated with methylprednisolone pulse therapy (500 mg iv once daily for 3 days), and antithymocyteglobulin (ATG)/ muromonab-CD3 (OKT3) was given in the event of steroidresistant rejection. Mycophenolate mofetil (MMF) was commonly added after rejection treatment and plasmapheresis was used in severe cases of antibody-mediated rejection.
CMV prophylaxis
The standard prophylaxis protocol in all CMV D+/R− renal transplant patients at our hospital was VACV 1 g thrice daily for 90 days after transplantation. Dose adjustment was based on renal function per manufacturer guidelines. Intravenous (iv) ganciclovir was used if patients were unable to take medication orally, or during ATG/OKT-3 treatment in the case of steroid-resistant rejection. The CMV prophylaxis in the CTS cohort during this period consisted of ACV/VACV (12%), GCV/VGCV (73%), immunoglobulin (15%) or any combination thereof.
CMV definitions, treatment and resistance
The virological methods employed during the study period were qualitative PCR and quantitative PCR (COBASRoche Amplicor or an in-house PCR [21] [22] ). The patients were not regularly monitored for viral replication but tested as soon as they experienced any symptoms consistent with CMV disease. CMV replication was determined to be present when CMV DNAemia was detected in the blood or serum. CMV disease was classified into three different categories: CMV syndrome, tissue-invasive CMV disease and clinical CMV disease. CMV syndrome required fever >38°C for >2 consecutive days and detection of CMV in blood or serum and any of the following symptoms: fatigue, malaise, artralgias, decreased renal function, leukopenia or elevated transaminases. Tissue-invasive disease required any of the above symptoms and detection of CMV in biopsies or other appropriate material according to the definition by Ljungman et al. [23] . Clinical CMV disease was any condition that did not fulfill the criteria listed above, but clinical judgement led to treatment with anti-CMV drugs. CMV disease was commonly treated with GCV iv (5 mg/kg twice daily) for 2-3 weeks with a subsequent reduction to 2.5 mg/kg twice a day according to clinical need. Since 2003, VGCV has also been used after the initial therapy with GCV iv, and since 2006 VGCV has occasionally been used as initial treatment. Therapy-resistant CMV disease was considered to be present if, despite four or more weeks of treatment with any anti-CMV drug, the antiviral therapy had to be switched and the CMV load in the blood failed to decline or CMV could be demonstrated in biopsies.
Neurotoxic adverse effects
Neurotoxic adverse effects were extracted from medical charts, nursing notes and study files for the entire prophylaxis period. VACV-induced major neurotoxic adverse effects were defined as the occurrence of hallucinations, confusion, anxiety or paranoia after the beginning of VACV prophylaxis.
Statistics
For univariate analysis, quantitative variables were compared using Student's t-test or Mann-Whitney U test
O R I G I N A L A R T I C L E
V A C V F o r C M V p r o p h y l a x i s i n r e n a l t r a n s p l a n t a t i o n whereas binary categorical variables were assessed using the χ 2 test or Fisher's exact test according to the sample size. The Kaplan-Meier method was used to estimate the patient and graft survival rates, and the results are indicated as mean percentages. All statistical tests were twotailed, and P < 0.05 was considered significant. Median values with ranges (minimum-maximum) were used unless stated otherwise. Statistical calculations apart from comparison between CTS and Uppsala data were made with the Statistica software (StatSoft, Inc., Tulsa, OK).
R E S U LT S
Patients
During the 10-year study period, 660 patients received a renal allograft. Of these, 121 patients were D+/R−, and 12 of the 121 had a combined renal-pancreas transplantation. Thus, 109 consecutive D+/R− renal transplant were assessed. Four patients were included in a rituximab study as a result of ABO incompatibility and were therefore excluded from the present study. Finally, one patient with both CMV and EBV seronegativity received VACV prophylaxis for 6 months, and two patients unintentionally did not receive any prophylaxis, leaving 102 patients who were included in the final study population (Table 1) .
Patient and graft survival and rejection
Two patients in our study population died during the first year after transplantation resulting in a 1-year patient survival of 98%. One of the patients died of a ruptured abdominal aortic aneurysm on Day 98, and the other died of an acute myocardial infarction on Day 141. Both patients experienced at least one episode of BPAR but died with functioning grafts. One of the patients was successfully treated for an episode of CMV syndrome between Days 60 and 100 with no sign of recurrence at the time of death.
Three patients lost their grafts during the first year of follow-up: one patient lost the graft as a result of a massive thrombosis on Day 6, one as a result of a post-surgical bleeding on Day 30, and one as a result of graft rejection on Day 100. Including the two patients who died, the 1-year graft survival was 95%. During the first year after transplantation, the total rejection frequency was 22% ( Table 2 ). The mean time to rejection was 50.2 ± 58.0 days (median 28 days; range, 5-236) and the rejection was classified as Banff I (A + B) in 52% and Banff II (A + B) in 48% of the cases. Rejection was generally treated with steroids (96%), and in six cases (26%) ATG or OKT-3 was given. Five-year patient and graft survival rates were compared with the corresponding data from the CTS database (Figures 1 and 2) , and there was no significant difference between the Uppsala population and the CTS cohort data. 
CMV disease
In total, 26 patients (25%) were diagnosed with CMV disease during the first year post-transplantation. Tissue-invasive CMV disease was diagnosed in two patients: one with CMV colitis on Day 59 and one with CMV pneumonitis and suspected CMV retinitis on Day 191. CMV syndrome was diagnosed in eight patients, median 131 days post-transplant (range, 91-176) and clinical CMV disease in 16 patients, median 115 days post-transplant (range, 26-170). Treatment of CMV disease was initiated with GCV iv in 24 patients and with VGCV in 2 patients, and the median length of treatment was 21 days (range, 14-150). Recurrence was seen in two patients. CMV disease was more frequently seen in patients treated with MMF (P = 0.001), whereas patients treated with basiliximab developed less CMV disease (P = 0.047).
Neurotoxic adverse effects of VACV prophylaxis
Major neurotoxic adverse effects were seen in two (2%) of the examined patients. One patient developed confusion on Day 31 and one patient experienced episodes of hallucinations on Days 23 and 119. The neurotoxic effects disappeared in both patients without discontinuation of VACV prophylaxis and might have been related to other causes such as high doses of morfin.
D I S C U S S I O N
In this retrospective study, we have evaluated the use of lowdose VACV prophylaxis in 102 consecutive D+/R− renal transplant patients. Patient and graft survival rates for the first 5 years post-transplantation and the incidence of acute graft rejection during the first post-transplant year were comparable with those observed in D+/R− renal graft recipients with CMV prophylaxis in the CTS registry (Figures 1 and 2 ) [1] . The baseline characteristics of our transplant population and patients in the CTS database were generally similar (Table 1) . Differences in the distribution of underlying diseases causing end-stage renal failure might be related to less precise reporting of diagnosis to the CTS database. The figures from our center are comparable with those from other Swedish centers during the same period [24] . The lower degree of HLA mismatch and slightly lower age of both donors and recipients in the CTS cohort should have favoured a better outcome in this group. On the other hand, the shorter cold ischemia time should have been an advantage for graft survival in our population. The frequency of CMV disease in our population, 25%, is in the upper range when compared with other prophylaxis studies [13, 14, 20] . This relatively high frequency may be attributed to the wide definition of CMV disease in our study. When the stricter criteria for CMV syndrome and tissue-invasive disease were used, the incidence of CMV disease was 10%. In general, CMV morbidity was a minor problem in our patients, most infections were easily treated, and only a few patients required repeated treatment. We found a correlation between the use of MMF and an increased risk of CMV disease, whereas the use of basiliximab, an IL-2 receptor antagonist, seemed to reduce the development of CMV disease. These findings have been described before [25] [26] [27] [28] . The increased risk associated with MMF might be explained by the fact that in our patients this drug was used more often after rejection. The favorable effect of basiliximab can probably be attributed to its high selectivity, since it affects only activated lymphocytes rather than producing the massive lymphocyte depletion associated with polyclonal antibodies. The risk for acute rejection in the D+/R− population has been reported to be high, 32-55%, but CMV prophylaxis has been shown to reduce this risk to 20-26% [13, 14, 29, 30] . Thus, the rejection frequency of 22% found in our study is consistent with the published data. We Table 1 . Baseline characteristics of the Uppsala patients (n = 102), compared with data from the Collaborative Transplant Study Group (CTS; n = 3904) Patients were CMV D+/R− and received anti-CMV prophylaxis. Values are expressed as mean ± SD. NS, no significance.
O R I G I N A L A R T I C L E
V A C V F o r C M V p r o p h y l a x i s i n r e n a l t r a n s p l a n t a t i o n did not see the high incidences of major neurotoxic adverse effects that has been reported in studies using high-dose VACV [13, 15, 16, 31] The number of major neurotoxic adverse effects in our study was comparable with the placebo levels reported by Lowance et al. [13] . An important aspect of comparative CMV prophylaxis studies is the cost of the various strategies. Earlier studies have concluded that prophylaxis with high-dose VACV or oral GCV is comparable with regard to cost, and that both regimens are highly cost-effective when compared with placebo [30, 31] . During the last years, there has been a substantial reduction in the price of VACV and the present cost of a low-dose VACV strategy would not exceed that of highdose VACV and VGCV, provided that the incidence of CMV disease is the same. The current cost for 90 days of VGCV prophylaxis in Sweden is 4900 EUR (900 mg × 1) and 2950 EUR (450 mg × 1), which is substantially higher than that of low-dose VACV for 90 days (1 g × 3) , which currently costs 105 EUR. The emergence of resistance is a matter of increasing concern. In patients with CMV disease who are infected with drug-resistant virus, the clinical outcome is generally poor, with a mortality rate of up to 20% [32] [33] [34] . The incidence of GCV-resistant CMV in a D+/R− renal transplant population has been estimated to be as high as 5% [32] . In an article by Eid et al. [33] , in which VGCV prophylaxis was used in solid organ transplant patients, as many as 14% of the patients with CMV disease had drug-resistant virus, and the frequency in another study of D+/R− renal recipients was 12.5% [35] . One way to reduce GCV-resistant CMV might be to reserve GCV for treatment and to use other compounds, such as VACV, for prophylaxis. In a study of VACV prophylaxis by Alain et al. [36] , a very low incidence of GCV resistance was demonstrated, and it was postulated that VACV may be less likely to select UL97-mutated GCV-resistant strains when compared with GCV.
CMV remains an important pathogen in transplant patients and various prophylactic and pre-emptive strategies have been developed to decrease the risk of CMV disease in Table 2 . Clinical outcome at 1 year after transplantation in D+/R− renal transplant patients with low-dose VACV (3 g/day) prophylaxis for a median of 90 days after transplantation (n = 102, 97 patients with a functioning graft). different transplant populations [16, 32, 37, 38] . Evidencebased guidelines [39, 40] have recommended universal prophylaxis for patients at the highest risk for CMV disease, whereas pre-emptive therapy was suggested to be most appropriate for those at a moderate or low risk for CMV disease. In the high-risk D+/R− renal transplant population, highdose VACV prophylaxis has been proved effective [13] and comparable with oral GCV [30] , and it was demonstrated that the efficacy of oral GCV is comparable with that of VGCV [14] . However, the occurrence of neurotoxic side effects such as hallucinations and confusion has limited the use of high-dose VACV. The advantage of using low-dose (3 g/day) VACV prophylaxis when compared with high-dose VACV (8 g/day) is a lower incidence of major neurotoxic adverse effects, and when compared with VGCV/GCV the advantage is less bone marrow toxicity. In addition, there is possibly less development of GCV resistance and there is a potential cost reduction. The present study is a retrospective study of CMV-mismatched (D+/R−) renal transplant patients at a single center and we recognize that it has limitations. 
V A C V F o r C M V p r o p h y l a x i s i n r e n a l t r a n s p l a n t a t i o n During the course of the follow-up period in this study, which was as long as 10 years, different immunosuppressive protocols have been used and surgical techniques, postoperative care and diagnostic procedures have improved. Another contributing cause to the lower incidence of CMV disease could be the low use of MMF and ATG at our center. The potential limitations of our study also include the absence of comparison with GCV/VGCV prophylaxis or pre-emptive therapy. Low-dose VACV prophylaxis was administrated for a median of 90 days, but there was a substantial variation. The variation in length could however not be connected to CMVrelated problems except when prophylaxis was ended early due to CMV disease. Late start and prolongation were mostly due to individual errors and not due to any medical reasons. The assessment of major neurotoxic adverse effects could potentially have been underestimated in a retrospective analysis such as ours, but these patients were meticulously monitored and the risk that major neurotoxic adverse effects such as hallucinations, confusion or paranoia were not reported can be virtually excluded. The strengths of this study include its comparatively large and homogenous D+/R− renal transplant population and the access to comparable data from the large CTS database, including baseline characteristics and 5-year patient and graft survival rates.
In conclusion, we have demonstrated that low-dose VACV prophylaxis (3 g/day) for a median of 90 days post-transplantation in D+/R− renal transplant patients results in high 5-year graft and patient survival and an incidence of CMV disease and acute rejection comparable with that obtained with other prophylactic strategies. Low-dose VACV prophylaxis is associated with low cost, is safe and allows to reserve GCV for the treatment of CMV disease. We believe that lowdose VACV prophylaxis should be considered to form one of the arms in future prospective comparison studies for the prevention of CMV disease in the high-risk D+/R− population of renal transplant patients.
